Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986410 + BMS-986409
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BMS-986410 + BMS-986409 is an investigational combination therapy developed by Bristol Myers Squibb for the treatment of advanced solid tumors, including metastatic castration-resistant prostate cancer. Both agents are novel immuno-oncology drugs under clinical evaluation. While detailed mechanisms of action for each agent are not fully disclosed in public sources, they are being studied together as part of a strategy to enhance anti-tumor immune responses in cancers that have progressed despite standard therapies[3][1]. The combination is currently being evaluated in early-phase clinical trials to assess safety and tolerability.
- Other names
- gridegalutamide
02
Targets
AR (Adrenergic receptors)CRBN (Cereblon)
Beyond the preview
Go deeper on BMS-986410 + BMS-986409.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986410 + BMS-986409.